Abstract
Hepatocyte growth factor (HGF), a c-Met ligand involved in cancer tumorigenesis and metastasis, mediates resistance to radiation and drives resistance to ErbB1 inhibitors such as erlotinib. Here we tested whether plasma HGF levels correlate with outcomes after definitive radiation for non-small cell lung cancer (NSCLC) and evaluated the role of HGF in radiosensitivity of NSCLC cells with high or low c-Met expression.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Radiation Oncology*Biology*Physics
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
